Tempest Therapeutics (TPST) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Jul, 2026Executive summary
A special meeting of stockholders is scheduled for July 27, 2026, to vote on a single proposal regarding amendments to the certificate of incorporation.
The proposed amendment aims to replace specified supermajority voting requirements with majority-of-outstanding standards and permit stockholder action by written consent.
The board unanimously recommends approval, citing alignment with modern governance practices and increased stockholder participation.
If approved, the amendment will be filed with the Delaware Secretary of State and may trigger conforming bylaw changes.
Voting matters and shareholder proposals
The sole proposal is to approve a Certificate of Amendment to the Restated Certificate of Incorporation, eliminating certain supermajority voting provisions and allowing stockholder action by written consent.
Approval requires at least 75% of votes entitled to be cast in any annual election of directors.
Stockholders may vote online, by phone, mail, or during the virtual meeting; beneficial owners must obtain a proxy from their broker to vote online.
Stockholder proposals for the 2026 annual meeting must be submitted between September 29 and October 29, 2026, or by September 8, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
The board has determined that the current supermajority and written consent restrictions may unduly limit stockholder participation and recommends modernization.
The amendment would allow bylaw changes by a majority of directors or stockholders, replacing higher thresholds.
Special meetings may only be called by the board or CEO, not by stockholders.
Latest events from Tempest Therapeutics
- Lead in vivo CAR-T asset targets broad autoimmune and oncology markets with scalable, modular delivery.TPST
Corporate presentation17 Jul 2026 - Proposal seeks to replace supermajority voting with majority standards and allow written consent.TPST
Proxy filing7 Jul 2026 - Biotech registers 2.4M shares for resale; proceeds from warrant exercises fund operations.TPST
Registration filing26 Jun 2026 - Amezalpat improved median OS by six months and doubled response rates in first-line HCC.TPST
Study Update19 Jun 2026 - Approval sought for major warrant-related share issuances to support liquidity and Nasdaq compliance.TPST
Proxy filing8 Jun 2026 - Shareholders to vote on major stock issuances tied to PIPE and Inducement Warrants, with Board support.TPST
Proxy filing29 May 2026 - Q1 2026 saw a $27.7M net loss, $1.8M cash, and urgent financing needs amid pipeline progress.TPST
Q1 202614 May 2026 - TPST-2003 dual CAR-T achieves deep, durable responses and strong safety in rrMM, including EMD.TPST
Corporate presentation11 May 2026 - Biotech registers 2.78M shares for resale; proceeds from warrant exercises support operations.TPST
Registration filing2 Apr 2026